MALAT1 expression is associated with aggressive behavior in indolent B-cell neoplasms

Area of Science:

• Molecular Biology
• Oncology
• RNA Biology

Background:

• MALAT1 long non-coding RNA (lncRNA) exhibits oncogenic properties but remains understudied in indolent B-cell neoplasms.
• Understanding MALAT1's role is crucial for advancing the diagnosis and treatment of these hematologic malignancies.

Purpose of the Study:

• To investigate the expression and clinical significance of MALAT1 in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).
• To explore the association of MALAT1 with prognostic factors and disease pathophysiology in indolent B-cell neoplasms.

Main Methods:

• Analyzed MALAT1 expression using RNA-sequencing, microarrays, and qRT-PCR in primary samples from CLL (n=266), Richter transformation (RT, n=6), and FL (n=61).
• Correlated MALAT1 levels with clinical parameters, including time to treatment and progression-free survival.
• Investigated co-expressed genes in CLL to identify associated oncogenic pathways.

Main Results:

• High MALAT1 expression in peripheral blood CLL samples was linked to a shorter time to treatment, independent of other prognostic factors.
• MALAT1 levels in CLL were similar between peripheral blood and lymph node samples, suggesting mirroring of microenvironment signals.
• In follicular lymphoma, elevated MALAT1 expression predicted shorter progression-free survival.
• MALAT1 expression in Richter transformation samples was lower compared to CLL.

Conclusions:

• MALAT1 expression is associated with the pathophysiology and aggressive clinical behavior of indolent B-cell neoplasms.
• In CLL, MALAT1 may serve as a surrogate marker for microenvironment stimulation, potentially aiding in refined clinical management.
• MALAT1 warrants further investigation as a prognostic and potentially therapeutic target in indolent B-cell neoplasms.